The peptide, whose sequence has been determined as Thr-Lys-Pro-Arg (Nishioka et al., 1972 (Nishioka et al., , 1973a , has been chemically synthesized by various investigators (Nishioka et al., 1972 (Nishioka et al., , 1973b Spirer et al., 1975; Yajima et al., 1975; Okamoto & Shimamura, 1976; Konopinska et al., 1977; Fridkin et al., 1977) . The physiological significance of tuftsin has been demonstrated in splenectomized dogs and humans (Najjar & Constantopoulos, 1972;  Constantopoulos et al., 1 973a; Spirer et al., 1977a, b) and also in patients with acute myelocytic leukemia (Constantopoulos et al., 1973b) whose low levels of serum tuftsin coincide with a high incidence of infections. Its exigency is further demonstrated in patients with a congenital tuftsin abnormality. Such infectionsusceptible individuals carry a peptide which competes with tuftsin (Najjar & Constantopoulos, 1972; Constantopoulos et al., 1973a) . In addition to human and dog PMNs, tuftsin has been shown to stimulate the phagocytic activity of guinea-pig peritoneal granulocytes, mouse peritoneal macrophages, and rabbit alveolar macrophages (Constantopoulos & Najjar, 1972) . Tuftsin also enhances the reduction of nitrous blue tetrazolium by human PMNs (Spirer et al., 1975; Fridkin et al., 1977) , the random migration of human mononuclear cells (Nishioka, 1976 (Nishioka, , 1978 and antigen-specific macrophagedependent education of T lymphocytes (Tzehoval et al., 1978) . Recently, the presence of specific binding sites for tuftsin on human PMNs and monocytes has also been revealed .
We present here the results of a preliminary study of the immunological functions of tuftsin, which indicate that this peptide can have immunological anti-tumour effects. These results suggest a potential role for tuftsin as an immunotherapeutic agent, not only for patients with Hodgkin's and other diseases requiring splenectomy, but also for patients with other tumour types.
In order to examine the anti-tumour activity of tuftsin, an in vivo syngeneic system of DBA mice and L1210 leukaemia cells was used. Control mice were injected i.p. with 104 L1210 cells. Experimental mice also received simultaneously in addition, 0-2 ,ug of tuftsin. The Figure (Nishioka, 1976 (Nishioka, , 1978 and macrophages (Constantopoulos & Najjar, 1972) in addition to PMNs (Fidalgo & Najjar, 1967; Najjar and Nishioka, 1970) , we attempted to examine another property of the activated macrophages, the morphological alteration or spreading after injection of tuftsin into the peritoneal cavity. CBA mice were injected with either 1 ml of sterile saline containing 10 [g of tuftsin or 1 ml of sterile saline alone. After 4 and 7 days, 2 mice were killed. The harvested pooled peritoneal exudate was plated on plastic Petri dishes, incubated in Hanks' solution for 2 h at 37°C and the phase-dark cells counted as described by Leonard & Skeel (1976 In addition, the total leucocyte count in the pooled peritoneal exudate increased from 1U4x 107 at Day 3 to 2 5x 107 at Day 7 after tuftsin injection, whereas the exudate from saline-injected mice gave 15x 107 at both Days 3 and 7.
In view of these observations, the effect of tuftsin on the cytotoxicity of peritoneal macrophages against IL 1210 cells was examined in vitro by adapting method described by Bean et al. (1976 incubated with 0, 1 or 10 ,ug tuftsin per ml MEM-NEAA (6 wells for each) at 37°C for 18 h and washed twice with MEM-NEAA to remove the remaining tuftsin. One fifth of 1 ml of MEM-NEAA containing 2,000 labelled Ll1210 cells was then introduced into each well to produce a ratio of macrophages:target cells of 50:1. After either 48 or 72 h incubation at 37°C, the L1l210 cells were collected from each well by a harvester and the radioactivity in the remaining viable L1210 cells counted using a liquid scintillation counter. As shown in the Table, the macrophages treated with 10 Htg tuftsin per ml showed consistently significant higher cytotoxicity than the untreated macrophages.
To rule out the possibility of the direct 
